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In dermatological practice, allergy to topical corticosteroids used to treat eczema is a recognized and 
common event. The typical presentation is of an eczema which fails to improve or deteriorates with 
treatment. Topical corticosteroids are also used to treat mucosal disease. This study assesses allergy to 
inhaled corticosteroids in asthmatics. In the patient group selected, there was no evidence of relevant 
corticosteroid allergy. 
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Introduction 
In dermatological practice, contact hypersensi- 
tivity from topical corticosteroids is becoming 
increasingly recognized, with prevalence rates of 
steroid allergy of up to 5% of patients attending 
contact dermatitis clinics (1). Clinically, the 
patients have a delayed-type (type IV) hypersen- 
sitivity which manifests as a worsening or lack of 
response of their dermatitis to treatment (1). 
Contact hypersensitivity is not limited to the 
skin; there are several reports of worsening of 
perennial rhinitis from the use of budesonide 
(224) and tixocortol pivalate (5-7) often in 
association with a perinasal dermatitis, and con- 
junctivitis following the use of eye drops con- 
taining betamethasone (8) and other steroids (9). 
Whilst there are reports of cough and broncho- 
spasm from inhaled corticosteroids, these have 
usually been assumed to be due to the vehicle 
(10-14). Rarely has it been suggested that the 
corticosteroids beclomethasone dipropionate 
(15,16), or budesonide (17) might have been the 
cause. Allergic reactions to inhaled corticosteroids 
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have been reviewed (18). The aim of the present 
study was to systematically investigate patients 
with asthma to see if steroid allergy is a more 
common problem than is currently suspected. 
Patients and Methods 
Patients with moderate/severe asthma were 
asked to participate in the study. Intradermal 
tests with 1 mg budesonide, 1 mg beclometha- 
sone dipropionate and 1 mg methyl prednisolone 
(pure steroid a gift of the manufacturers) sus- 
pended in 0.1 ml sterile normal saline, and 1 mg 
hydrocortisone sodium succinate (Solu-Cortep, 
Upjohn) in a volume of 0.1 ml sterile normal 
saline were performed. The excipients of the 
preservative-free preparation of hydrocortisone 
sodium succinate are sodium phosphate and 
sodium biphosphate (pers. comm.). At the time 
of testing, no patient was taking an oral anti- 
histamine. Readings were taken at 30 min and 
48 11. A positive reaction at 30 min was defined as 
the presence of a flare > 1 cm or wheal and flare 
>0.5 cm larger than that occurring to a control 
injection of normal saline. At 48 h, the test 
was considered positive if an area of indurated 
erythema >0.5 cm was present. Antibodies to 
hydrocortisone were detected by ELISA (19). 
Serum from 17 patients with positive patch test 
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reactions to nickel sulphate (5% pet) who had 
been exposed to topical hydrocortisone, and 40 
blood donors was used as controls. 
Results 
Sixty-five patients were tested [29 male, 36 
female; average age 53 years (SD f 13.6)], with 
an average duration of asthma 19.5 yr (SD f 
14.6). Fourteen and 51 individuals were using 
inhaled preparations containing budesonide 
and beclomethasone dipropionate, respectively. 
Systemic prednisolone at a dose of less than 
10 mg daily was being taken by four patients for 
their asthma. 
Seven patients had eczema, 24 had hayfever 
and eight had nasal polyps. Of the patients with 
eczema, five were using a topical steroid (two 
using hydrocortisone-17-butyrate and three us- 
ing hydrocortisone). Two patients have a history 
of aspirin-induced aggravation of their asthma. Nickel Control Asthma 
Two individuals had positive skin tests at 
30 min, and none had a reaction at 48 h. Of the 
two individuals with immediate reactions, one 
had a reaction to hydrocortisone and was using 
this topically for seborrhoeic eczema. The other 
patient had reactions to both hydrocortisone 
and budesonide, but was using a beclometha- 
sone dipropionate inhaler. He gave a history of 
having previously using a budesonide nasal 
spray for hayfever which was discontinued 
because of a lack of clinical effect. 
FIG. 1. Optical density at 405 nm after incubation 
with alkaline phosphatase labelled anti-human IgG. 
(Bars indicate 95% confidence intervals for the 
mean). Nickel, patients with delayed-type hypersen- 
sitivity to nickel exposed to topical hydrocortisone; 
control, blood donors; asthma, asthmatic patients 
with immediate-type reactions to hydrocortisone. 
Serum from both individuals did not contain 
IgE, IgA or IgM antibodies to hydrocortisone by 
ELISA. The results for IgG antibodies are 
shown in Fig. 1. 
Discussion 
Two patients had aspirin sensitivity but 
neither had experienced any problems from the 
use of corticosteroids. Anaphylactoid reactions 
to hydrocortisone have been associated with 
aspirin-sensitive asthma. In these patients, an 
anaphylactoid response can occur as a result of 
an idiosyncratic reaction to the succinate ester. 
Skin tests are negative (20) and the reaction has 
been reproduced with chloramphenicol succinate 
(21). 
There were no patients in this group with In dermatological patients, the cutaneous 
moderate/severe asthma who had delayed-type reactions have been shown in vitro, using lym- 
hypersensitivity to corticosteroids. Two individ- phocyte transformation assays, to be manifesta- 
uals had immediate reactions. In one, the clinical tions of delayed-type hypersensitivity (22,23). 
relevance was doubtful, whilst the other, Cutaneous immediate-type hypersensitivity reac- 
with reactions to both hydrocortisone and tions have not been seen following topical use, 
budesonide, gave a history of lack of effect of although N 30% of individuals with delayed-type 
a budesonide-containing nasal inhaler. Using hypersensitivity have immediate reactions 
ELISA, antibodies to hydrocortisone could not 30 min following an intradermal injection, and 
be detected in the patient with a reaction to IgG antibodies to hydrocortisone have been 
budesonide. In the other patient, an absorbency demonstrated by ELISA (19). The lack of any 
greater than 3 SDS above the mean of the control demonstrable IgE-mediated hypersensitivity 
groups suggested the presence of IgG antibodies. reaction may reflect the possibility that 
corticosteroids preferentially stimulate the devel- 
opment of delayed-type hypersensitivity (24). 
Another possible explanation for the low level 
of steroid sensitivity could be that the majority of 
patients were using beclomethasone dipropion- 
ate, which has been shown to result in relatively 
few cutaneous contact hypersensitivity reactions 
in comparison to budesonide (25). When used 
cutaneously, budesonide has been estimated to 
induce hypersensitivity 77 times more frequently 
than bethamethasone valerate (26). Whilst the 
authors feel that this study contained an ad- 
equate number of patients taking beclometha- 
sone dipropionate, it was difficult to recruit 
large numbers of patients using budesonide, and 
further study of this group may be warranted. 
In conclusion, in contrast to patients with 
dermatitis attending for investigation of sus- 
pected contact allergy, patients with asthma 
were found to have a low prevalence of clinically 
relevant corticosteroid hypersensitivity. 
References 
1. Wilkinson SM. Hypersensitivity to topical corti- 
costeroids. Clin Exp Dermatol 1994; 19: l-11. 
2. Meding B, Dahlberg E. Contact allergy to 
budesonide in a nasal spray. Contact Derm 1986; 
14: 253-254. 
3. Jerez J, Rodriguez F, Garces M et al. Allergic 
contact dermatitis from budesonide. Contact 
Derm 1990; 22: 23 1. 
4. Peris-Tortajada A, Giner A, Perez C et al. Con- 
tact allergy to topical budesonide. J Allergy Clin 
Immunol 1991; 78: 597-598. 
5. Boujna-Khouadja A, Brandle I, Reuter G, 
Foussereau J. Allergy to 2 new corticoid mol- 
ecules. Contact Derm 1984; 11: 83-87. 
6. Camarasa JG, Malet A, Serra-Baldrich E, Lluch 
M. Contact allergy to tixocortol pivalate. Contact 
Derm 1988; 19: 147-148. 
7. Bircher AJ. Short induction phase of contact of 
allergy to tixocortol pivalate in a nasal spray. 
Contact Derm 1990; 22: 237-238. 
8. Alani SD, Alani MD. Allergic contact dermatitis 
and conjunctivitis to corticosteroids. Contact 
Derm 1976; 2: 301-304. 
9. Lewis FM, Gawkrodger DJ, Bleehen SS, Nelson 
ME. Multiple contact sensitivity to eyedrops. 
Contact Derm 1993; 28: 246-247 
10. Bryant DH, Pepys J. Bronchial reactions to aero- 
sol inhalant vehicle. BMJ 1976; i: 1319. 
STEROID HYPERSENSITIVITY IN ASTHMA 233 
11. Godin J, Malo JL. Acute bronchoconstriction 
caused by Beclovent and not Vanceril. Clin 
Allergy 1979; 9: 585-589. 
12. Maddern PJ, Oh TE, Elphick HR: Paterson JW. 
Adverse reaction after aerosol inhalation. Med J 
Aust 1978; i: 274. 
13. Shim CS, Williams MH. Cough and wheezing 
from beclomethasone dipropionate aerosol are 
absent after triamcinolone acetonide. Ann Intern 
Med 1987; 106: 700-703. 
14. Shim CS, Williams MH. Cough and wheezing 
from beclomethasone aerosol. Chest 1987; 91: 
207-209. 
15. Clark RJ. Exacerbation of asthma after nebulised 
beclomethasone dipropionate. Lancet 1986; II: 
574-575. 
16. Poh SC: Wang YT. Severe bronchoconstriction 
after inhalation of beclomethasone and budeso- 
nide. Singapore Med J 1986; 27: 247-249. 
17. McGivern DV, MacFarlane JT. Severe bron- 
choconstriction after inhalation of budesonide. 
BMJ 1984; 288: 447. 
18. Dooms-Goosens A. Allergy to inhaled corticos- 
teroids: a review. Am J Contact Derm 1995; 6: 1-3. 
19. Wilkinson SM, Mattey DL, Beck MH. IgG anti- 
bodies and early intradermal reactions to hydro- 
cortisone in patients with cutaneous delayed-type 
hypersensitivity to hydrocortisone. Br J Dermatol 
1994; 131: 495498. 
20. Szczeklik A, Nizankowska E, Czerniawska- 
Mysik G, Sek S. Hydrocortisone and airflow 
impairment in aspirin-induced asthma. J Allergy 
Clin Immunol 1985; 76: 530-536. 
21. Taniguchi M, Sato A. Aspirin induced asthmatics 
(AIA) have cross-sensitivity with the steroid suc- 
cinate esters. N Eng Reg Proc Allergy 1988; 9: 
338. 
22. Lauerma AI, R&&en L, Reunala T, Reitamo S. 
Langerhans cells but not monocytes are capable 
of antigen presentation in vitro in corticosteroid 
contact hypersensitivity. Br J Dermatol 1990; 
123: 699-705. 
23. Wilkinson SM, English JSC, Mattey DL. In vitro 
evidence of delayed-type hypersensitivity to 
hydrocortisone. Contact Derm 1993; 29: 241-245. 
24. Dearman RJ, Kimber I. Differential stimulation 
of immune function by respiratory and contact 
chemical allergens. Immunology 1991; 72: 563- 
570. 
25. Boffa M, Wilkinson SM, Beck MH. Screening for 
corticosteroid contact hypersensitivity. Contact 
Derm 1995; 33: 149-151. 
26. Okano M. Contact dermatitis due to budesonide: 
report of 5 cases and review of the Japanese 
literature. Int J Dermatol 1994; 33: 709-715. 
